HebeCell develops and commercializes cell-based therapeutics to treat incurable diseases.
HebeCell has raised $53.0M in total funding. The most recent round was Series A. The last funding was announced in August 2021.
HebeCell's investors include Jacobio Pharmaceuticals, Aceso Biotech Venture Fund.
HebeCell is headquartered in Natick, United States.
HebeCell develops and commercializes cell-based therapeutics to treat incurable diseases.
HebeCell is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HebeCell — Funding & Investors." VCBacked, August 31, 2021, https://www.vcbacked.co/company/hebecell. Accessed September 30, 2026.
VCBacked. (2021). HebeCell — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/hebecell
{{cite web |title=HebeCell — Funding & Investors |url=https://www.vcbacked.co/company/hebecell |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated